Capmatinib Dosage

Medically reviewed by Drugs.com. Last updated on Sep 16, 2022.

Usual Adult Dose for Non-Small Cell Lung Cancer

400 mg orally 2 times daily

Use: For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an approved test

Renal Dose Adjustments

Mild (CrCl 60 to 89 mL/min) to moderate (CrCl 30 to 59 mL/min): No adjustment recommended.
Severe (CrCl 15 to 29 mL/min): Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

DOSE MODIFICATION RECOMMENDATIONS:

• First dose reduction: 300 mg orally 2 times daily
• Second dose reduction: 300 mg orally 2 times daily
• Permanently discontinue this drug in patients who are unable to tolerate 200 mg orally 2 times daily.

DOSE MODIFICATION FOR ADVERSE REACTIONS:
INTERSTITIAL LUNG DISEASE (ILD)/PNEUMONITIS:

• Any Grade: Permanently discontinue this drug.

Increased ALT and/or AST without increased total bilirubin:

• Grade 3: Withhold therapy until recovery to baseline ALT/AST; if recovered to baseline within 7 days, resume this drug at the same dose; otherwise resume at a reduced dose.
• Grade 4: Permanently discontinue this drug.

INCREASED ALT AND/OR AST WITH INCREASED TOTAL BILIRUBIN IN THE ABSENCE OF CHOLESTASIS OR HEMOLYSIS:
ALT and/or AST greater than 3 times the upper limit of normal (ULN) with total bilirubin greater than 2 x ULN: Permanently discontinue this drug.
INCREASED TOTAL BILIRUBIN WITHOUT CONCURRENT INCREASED ALT AND/OR AST:

• Grade 2: Withhold therapy until recovery to baseline bilirubin; if recovered to baseline within 7 days, resume this drug at the same dose; otherwise resume at a reduced dose.
• Grade 3: Withhold therapy until recovery to baseline bilirubin; if recovered to baseline within 7 days, resume this drug at reduced dose; otherwise permanently discontinue this drug.
• Grade 4: Permanently discontinue this drug.

OTHER ADVERSE REACTIONS:

• Grade 2: Maintain dose level; if intolerable, consider withholding this drug until resolved, then resume at a reduced dose.
• Grade 3: Withhold this drug until resolved then resume at reduced dose.
• Grade 4: Permanently discontinue this drug.

Precautions

CONTRAINDICATIONS:

• None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• This drug may be taken with or without food.
• Tablets should be swallowed whole; not broken, crushed, or chewed.
• If a dose is missed or vomited, do not make up the dose but take the next dose at its scheduled time.

Storage requirements:

• Dispense this drug in the original package with the desiccant cartridge.
• Store at 20C to 25C (68F to 77F), excursions permitted between 15C to 30C (59F to 86F).
• Protect from moisture.
• Discard any unused drug remaining after 6 weeks of first opening the bottle.

Frequently asked questions

• How effective is Tabrecta?

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer